Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Clinical Trial to Evaluate Safety and Efficacy of Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Non-responders to the Conventional Treatment With Ranibizumab

NCT01136252 is registered in ClinicalTrials.gov with Hospital Universitari Vall d'Hebron Research Institute as lead sponsor.

NCT NCT01136252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01136252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Clinical Trial to Evaluate Safety and Efficacy of Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Non-responders to the Conventional Treatment With Ranibizumab
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
October 31, 2011
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, choroidal neovascularization